We undertook a 28-year review of enteric fever at a large tertiary care pediatric center. Most cases occurred in children who visited friends and relatives in the Indian subcontinent, and there was significant antibiotic resistance. Documented vaccination rates were low, and many cases also had evidence of delays in diagnosis and treatment.
Enteric fever is a systemic infection caused by the Gram-negative bacillus Salmonella enterica subspecies enterica, serovar Typhi (Salmonella serovar Typhi, typhoid fever) or serovar Paratyphi A, B, or C (Salmonella serovar Paratyphi A, B, or C, paratyphoid fever). Humans are the only reservoir for Salmonella serovar Typhi and serovar Paratyphi A, B, or C, which are both spread via fecal-oral transmission [1] . Although public health measures have effectively eliminated domestic acquisition in Canada and effective vaccines exist, the disease continues to occur in this country mainly as a result of acquisition through travel. In areas with poor sanitation, food and water safety, and overcrowding, there continues to be an estimated 22 million cases and 200 000 deaths per year [2] , with infants and young children disproportionately affected [3] .
Another emerging issue has been the increasing rate of antimicrobial resistance, which has resulted in widespread shift of empiric therapy to third-generation cephalosporins from ampicillin, cotrimoxazole, and quinolones. A previous report from our province found that approximately 80% of Salmonella serovar Typhi isolates were fluoroquinolone resistant [4] .
The metropolitan Toronto area is one of the most ethnically diverse cities in North America, and changing trends in enteric fever diagnosed here reflect those of the changing global epidemiology. In 2011, Toronto Public Health described a 3-fold increase in the incidence of paratyphoid fever over the preceding 10 years. As expected, the incidence of both Salmonella serovar Typhi and serovar Paratyphi A, B, or C decreased with age, and the majority of patients had traveled to the Indian subcontinent [5] .
Although many studies have been published from low-and middle-income countries, pediatric-specific data in North America is lacking. This report aims to describe the epidemiology, microbiology, presentation, management, and outcomes of patients with enteric fever diagnosed or treated at a large tertiary care pediatric center over a 28-year period.
METHODS
We performed a retrospective chart review of children admitted with enteric fever at The Hospital for Sick Children, a large tertiary care pediatric center, from January 1985 to December 2013. Subjects were identified by discharge diagnoses and microbiology records and only included if they had blood or stool culture-confirmed Salmonella serovar Typhi or serovar Paratyphi A, B, or C infections. A standard form was used for all cases to collect clinical, demographic, travel, and microbiologic data.
Isolates were identified as Salmonella serovar Typhi or serovar Paratyphi A, B, or C by standard microbiological methods plus reference serotyping at the Ontario Public Health Laboratory. Antimicrobial susceptibility testing (AST) was performed according to the Clinical Laboratory Standards Institute (CLSI) guidelines, using automated broth microdilution (Phoenix; Becton Dickinson, Sparks, Maryland).
Charts from the year 2000 onwards were analyzed for timeliness of diagnosis (by number of visits with an attending physician) and initiation of definitive antibiotic therapy (defined as number of days to receiving treatment with an intravenous third-generation cephalosporin). The study was approved by the Research Ethics Board of the Hospital for Sick Children.
We identified 126 cases of microbiologically confirmed enteric fever, of which 102 (81%) were positive for Salmonella serovar Typhi and 24 (19%) were positive for Salmonella serovar Paratyphi A (n = 19) or B (n = 5). Tartrate status was not available for any of the Salmonella serovar Paratyphi B isolates. Eighty-eight cases were positive by blood culture alone, 14 by stool alone, and 24 in both specimens. All cases had blood cultures sent, and 71 of 126 (56%) cases had stool samples sent. The age range of the patients was 8 months to 17 years, with a mean age of 6.2 years. Forty-nine percent of children were female and 51% were male.
Over the study period, the annual number of cases of enteric fever increased over 3-fold, with an increasing proportion of cases in recent years caused by Salmonella serovar Paratyphi A or B. Of the total number of cases, 99 were travel related, 13 occurred in new immigrants, 12 were domestically acquired, and 2 were relapses. Of those who traveled from Canada, at least 89% were known to be visiting friends and relatives abroad (VFRs).
In 84 of 126 (67%) patients in whom vaccine status was documented, only 4 (4.7%) had received a typhoid vaccine before travel. As shown in Table 1 , 80% of cases were acquired during travel to the Indian subcontinent (India, Pakistan, or Bangladesh).
Of the 91 cases seen after the year 2000, patients visited a median of 3 attending physicians with a median interval of 4 days from initial presentation to receiving definitive treatment. Only by the eleventh day after presentation did 90% of patients receive appropriate antibiotics. In 64% of cases, patients were recalled to hospital after blood cultures returned positive. Although not standard practice, 2 patients were empirically started on ciprofloxacin with subsequent results showing resistance to that drug.
Presenting signs and symptoms are shown in Table 1 . All patients had documented fevers (oral or rectal temperature >38°C, or axillary temperature >37.5°C), with 71% of patients reaching a maximum temperature of >39°C. Gastrointestinal upset was common, particularly diarrhea, anorexia, and nausea or vomiting. Severe complications occurred in fewer than 10% of cases and included shock, disseminated intravascular coagulation, acute respiratory distress syndrome, renal failure, encephalopathy, and seizures. The "classic" signs of rose spots and relative bradycardia were rarely noted. Relapse was identified in 2 children, with microbiologic confirmation. Their isolates were susceptible to the antibiotics that had been administered, and they were re-treated with the same antibiotics on a longer parenteral course with full recovery.
Full susceptibility testing was available on 119 of 126 isolates. Only 48 of 119 (40%) isolates were fully susceptible to ciprofloxacin, ampicillin, and trimethoprim-sulfamethoxazole (TMP-SMX)-the drugs traditionally used to treat enteric fever. Strains resistant to both ampicillin and TMP-SMX were found in 29 of 119 (24%) cases, and of these, 23 isolates were also resistant (or nonsusceptible) to ciprofloxacin. All specimens were susceptible to third-generation cephalosporins. Ciprofloxacin resistance remained low until the CLSI guideline change in 2003, recommending the use of nalidixic acid as a more sensitive predictor of decreased susceptibility to ciprofloxacin [6] . This change contributed to an immediate rise in the reported combined rate of decreased susceptibility or frank resistance to ciprofloxacin, with recent rates varying between 80% and 85% (Figure 1 ).
DISCUSSION
The evolving multicultural demographic of North America has created a need for clinicians to be aware of diseases that are uncommonly acquired at home but easily acquired abroad and imported.
Several studies have noted that VFRs (particularly those from the Indian subcontinent) have been the group at highest risk for enteric fever [7] [8] [9] . This was borne out in our review, where at least 89% of our patients were VFRs and 80% of overall cases came from the Indian subcontinent. Those visiting friends and relatives tend to stay in local homes and eat in the same environment as their hosts, and they are likely to remain abroad for extended periods of time [10] . The rise in annual number of cases of enteric fever correlates with the changing demographics of the city and country at large. Canada now has the highest proportion of immigrants amongst the G8 countries, with over 30% choosing to settle in Toronto. The population of Toronto itself has doubled from 1.3 million to 2.8 million over the past decade, and the largest visible minority are South Asians at 12% of the population [11] .
Of the 84 patients with documented vaccination status, only 4 (4.7%) had received a typhoid vaccine. Similar rates were found by Steinberg et al [8] . The 2 typhoid vaccines, oral live-attenuated Ty21a vaccine and intramuscular capsular polysaccharide Vi vaccine, present several challenges. Efficacy has been estimated at between 50% and 80% [12] , neither vaccine is approved for use in children under 2 years of age, and boosters are required. Furthermore, there are currently no vaccines licensed against S serovar Paratyphi A, B, or C, which is becoming increasingly prevalent in endemic areas [13] , and as our data reflect, in North America as well. In this review, 14 children were below the age of 2 and therefore ineligible for vaccination.
Another key finding in this study is that children presenting with enteric fever often go unrecognized, leading to delays in diagnosis and treatment. The classic findings of fever, diarrhea, vomiting, anorexia, and abdominal pain were the most prominent in our patient population but are also quite nonspecific. Consistent with other studies, the diagnosis is often not considered until the cultures become positive for Salmonella serovar Typhi or Salmonella serovar Paratyphi A, B, or C [7] . Stool cultures are known to be less sensitive in the detection of the organism [9] and were positive in only 38 of 71 cases; however, in 14 of those cases (37%), the diagnosis was made by stool culture alone, thus highlighting their diagnostic importance.
Although many patients in this review received antibiotics soon after presentation, coverage for enteric fever was often inadequate. Global patterns of susceptibility and treatment have dramatically changed over the course of this review. Although initially chloramphenicol, ampicillin, and TMP-SMX were common first-line agents, the emergence of resistance shifted empiric treatment toward fluoroquinolones in the early 1990s [14] . Within a few years, treatment failures and resistance emerged as Salmonella serovar Typhi strains acquired a mutation in the gyrA gene encoding a subunit of DNA gyrase [14] . Between 2003 and 2007, the rate of nalidixic acid-resistant Salmonella serovar Typhi, was above 80% in Ontario [4] , thus rendering ciprofloxacin ineffective as a first-line agent.
Due to these emerging resistance patterns, current recommendations include initiating therapy with a third-generation cephalosporin such as ceftriaxone, with a total treatment duration of 10-14 days [15] . Cefixime is an effective oral alternative, and azithromycin is suitable for mild-to-moderate cases [14] [15] . These antibiotics are generally well tolerated, cost effective, and accessible. Due to high levels of resistance, ciprofloxacin is not a suitable first-line therapy, but it should be considered for susceptible strains, due to its cost, efficacy, and low rate of relapse.
Our study has some limitations. First, this is a retrospective review from a single pediatric facility. Second, changing practices in clinical and laboratory documentation over the 28-year period of review made it challenging to ensure all data were consistently available, particularly for clinical presentation. Finally, incidence rates and trends could not be calculated due to lack of denominators. 
CONCLUSIONS
Enteric fever remains a major, preventable global infectious disease, and this review highlights unique aspects of prevention, recognition, and management in resource-rich, multicultural settings. Children who travel to endemic areas to visit friends and relatives should be targeted for prevention through counseling and vaccination. The importance of a detailed travel history cannot be overestimated, and clinicians must consider enteric fever for any child returning with fever from the Indian subcontinent, particularly since symptoms are nonspecific. If the diagnosis is suspected, appropriate microbiologic testing including both blood and stool cultures should be obtained. If empiric antibiotic patterns are indicated, third-generation cephalosporins should be used until culture and AST results are available.
